SLE is a heterogeneous disease, which can cause many different manifestations and symptoms, and traditionally did not have many treatment options.
Erasca receives fast track designation for glioblastoma therapy
ERAS-801 is intended to treat patients with glioblastoma. Credit: Mikael Häggström, M.D./ commons.wikimedia.org. Erasca has received the US Food and Drug Administration’s (FDA) fast track